Tianfeng Securities: Initiates "Buy" rating for KHPG with a target price of 51.84 yuanZhitong·Oct 14, 2025 at 06:36 AM002773+1.47%
KHPG: Ipasitide tablets have obtained a drug registration certificateZhitong·Sep 29, 2025 at 04:06 AM002773+1.47%
KHPG: Criminals are using the company's name to carry out fraud and other activitiesZhitong·Aug 12, 2025 at 01:53 PM002773+1.47%
The concept of innovative drugs has strengthened again, with Hotgen rising over 10% to reach a new historical highZhitong·Aug 6, 2025 at 01:39 AM002773+1.47%688068-5.43%
KHPG: Currently, production and business activities are normal, and there are no significant matters that should be disclosed but have not been disclosedZhitong·Jul 21, 2025 at 10:36 AM002773+1.47%
KHPG: Received the drug registration certificate for Lifi Shite eye dropsZhitong·Jun 30, 2025 at 11:21 AM002773+1.47%
The innovative drug concept surged and then fell back, with Sinovac Biotech dropping over 10%36Kr·Jun 17, 2025 at 02:52 AM688799-6.14%002773+1.47%
KHPG's subsidiary Songling Xuemai Kang capsules approved for clinical trialsZhitong·Jun 11, 2025 at 12:11 PM002773+1.47%
May 30th Midday Review: The ChiNext Index fell 0.88% in half a day, while the innovative drug concept surged against the trendWallstreetcn·May 30, 2025 at 03:31 AM601838+1.26%002082-3.07%
KHPG's subsidiary injectable KH617 has been approved to conduct clinical trialsZhitong·May 26, 2025 at 03:51 AM002773+1.47%
KHPG: Injectable KH815 has received approval for clinical trialsZhitong·Apr 16, 2025 at 11:34 AM002773+1.47%